


Figure 1

Malignant Breast 96102003G H9C65




Malignant Breast 9609C033R H9C65



Normal Breast. 9712C030G H9C65



MB8 Cell Line H9C65



JOURNAL OF CLINICAL PATHOLOGY

Figure 2




Figure 3




Figure 4





Figure 5







Figure 6



Polyclonal Antisera, 1:5000



Monoclonal Antibodies 1:50

Figure 6 (cont'd)




Figure 7




Figure 8




Figure 9




Figure 10







Figure 11




anti-BU101.3, 10923, 1:5000
sample reduced and boiled



anti-MAM.1, 10931, 1:5000
sample reduced and boiled



Polyclonal Antibody 10923
anti-BU101.3



Polyclonal Antibody 10931
anti-MAM.1





Figure 14




Figure 15

FIGURE 16

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys
Cys
1 5 10 15
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu
Leu
20 25 30
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala
Lys
35 40 45
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys
Arg
50 55 60
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu
Val
65 70 75
80
Leu Val Lys Ile Leu Lys Lys Cys Ser Val
85 90

© 2002 WILEY

FIGURE 17

Assembly of BS106 from Individual Expressed Tags




Figure 18A

>BS106 consensus

CGGCTCGAGCTCTAGGCTTGAAGCATTGGTGTGCTCCCTGATCTTCAGGTACCCACC
A
TGAAGTCTTAGCAGTCCTGGTACTCTGGGAGTTCCATCTTCTGGTCTCTGCCAGAACATCC
GACAACAGCTGCTCCAGCTGACACGTTACGGTACTGGTCTGCTGATGATGAAGCCCCCTGA
TGCTGAAACCAGCTGCTGCAACCAGCTGCGACCAC TGCTGCTCCTACCACTGCAACCACCGC
TGCTTCTACCACTGCTCGTAAGACATTCCAGTTACCAAATGGGTTGGGGATCTTCCGAAT
GGTAGAGTGTGTCCTGAGATGGAATCAGCTTGAGTCTTCTGCAATTGGTCACAACATTCA
GCTTCCTGTGATTTCATCCAACACTACTACCTTGCTACGATATCCCCTTATCTTAATCAGTT
ATTTTCTTCAAAATAACTATGAGCAACATA AAAAAAAAAAAAAA


Figure 18B

>BS106 translation

MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAATTATTAAPTTATTAA
STTARKDIPVLPKWVGDLPNGRVC

Figure 19A

BU101



* Expression not detectable

Figure 19B

Mammaglobin





Figure 19C

BS106



Figures 20 A-D




Figure 21

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mammaglobin	CK19
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS) N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS) N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS) N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS) N=85
ER	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS) N=99
PR	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS) N=99
HER2	-0.12 (NS)	0.36 (p=0.003)	0.11 (NS)	0.02 (NS) N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS) N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS) N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS) N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS) N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. NS= not significant